BC Cancer Foundation

150 - 686 West Broadway
Vancouver, BC V5Z 1G1
President & CEO: Sarah Roth
Board Chair: Kirsten Tisdale

Charitable Reg. #:11881 8434 RR0001

STAR RATING

Ci's Star Rating is calculated based on the following independent metrics:

🔓
Unlock Charity Ratings

✔+

FINANCIAL TRANSPARENCY

Audited financial statements for current and previous years available on the charity’s website.

B

RESULTS REPORTING

Grade based on the charity's public reporting of the work it does and the results it achieves.

n/r

DEMONSTRATED IMPACT

The demonstrated impact per dollar Ci calculates from available program information.

NEED FOR FUNDING

Charity's cash and investments (funding reserves) relative to how much it spends on programs in most recent year.

69%

CENTS TO THE CAUSE

For a dollar donated, after overhead costs of fundraising and admin/management (excluding surplus) 69 cents are available for programs.



My anchor

Programs

About BC Cancer Foundation:

Founded in 1935, BC Cancer Foundation (BCCF) raises money for BC Cancer. BC Cancer runs six regional cancer centres in Abbotsford, Kelowna, Prince George, Surrey, Vancouver, and Victoria. These centres provide the full spectrum of cancer care to people living in BC, including prevention, diagnosis, treatment, and palliative care. BC Cancer also conducts cancer research. The Foundation’s grants fund research, major equipment purchases, and patient care. BCCF reports distributing $32.3m in grants to BC Cancer in F2020, which includes $1.3m in deferred grants to be paid in future years.

Research was 73% of grants in F2020. Funding goes to research on cancer prevention, genomics and personalized medicine, immunology, and nuclear medicine. The Personalized Onco-Genomics (POG) program is a precision medicine initiative that creates tailored treatment options for metastatic cancer patients using genomics. By reading a patient’s genome to find the cancer-driving genetic markers, doctors can better understand the root cause of the cancer and direct the patient to an appropriate targeted therapy clinical trial, if possible. As of August 2019, BCCF reports that 1,068 patients have consented to be enrolled in POG, and 84% of completed cases produced useful results that the doctor and patient could use in treatment planning.  The Foundation also funds BC Cancer Genome Sciences Centre. The Centre uses genome sequencing and bioinformatics to prevent and diagnose cancer, as well as identify new therapeutic targets for treatment. It is part of BC Cancer, and is the first genome centre embedded within a cancer system. Since it was established in 1999, the Centre has worked on 850 research projects, sequenced 660,000 human genomes, and published nearly 1,300 peer-reviewed articles that have been cited over 95,000 times.

Equipment purchases were 24% of grants in F2020. This funded a second mass spectrometer for BC Cancer. This piece of equipment takes detailed measurements of protein molecules to help researchers understand how cancer cells grow and evade therapies. Prior to this purchase, research teams had to wait up to two years to use the single available spectrometer. A new PET/CT cancer was purchased for the BC Cancer Centre in Victoria, which will increase capacity to scan up to 20 more patients per week. The Vancouver Centre now has a new Fujifilm endoscopy unit with high-resolution cameras. This unit is the first of its kind in Canada.

The remaining 3% of grants in F2020 were for patient care.

My anchor

Results and Impact

In F2020, BC Cancer researchers discovered new information about how Hodgkin lymphoma cells can grow undetected in the body and how they interact with other cells in the tumour micro-environment. The findings, which have been published in Cancer Discovery, show that the body’s own immune cells hide these lymphoma cells, sometimes even forming a shield around them. Lymphoma cells hijack normal immune cells to turn them into cancer-supporting, immune-suppressing cells. This discovery will help doctors come up with better personalized treatment options for patients.

A clinical trial of Stereotactic Ablative Radiotherapy (SABR) technology co-led by BC Cancer researchers found that SABR may improve survival rates of patients with limited metastatic cancers. SABR technology delivers pinpoint, high dose radiation over a shorter time frame than traditional radiation therapy. SABR can vary the radiation dose from multiple angles. This reduces the dosage to healthy tissue and ultimately improves cure rates while reducing the risk of side effects. The findings have been published in The Lancet.

BC Cancer researchers have also created a new pancreatic cancer treatment after identifying a rare genetic trait in some patients that is potentially treatable with targeted therapy. The findings have been published in Clinical Cancer Research and are a promising breakthrough for precision medicine.

My anchor

Finances

BC Cancer Foundation is a Major 100 charity, one of Canada’s largest in terms of donations. It received $55.1m in donations and special events fundraising in F2020. Administrative costs are 7% of revenues (excluding investment income) and fundraising costs are 24% of donations and special events fundraising. For every dollar donated, 69 cents go to the cause. This is within Ci’s reasonable range for overhead spending.

Funding reserves of $166.1m include $52.0m in endowed funds. BCCF’s audited financial statements do not disclose how much of these funds are donor endowed. Including all endowed funds, the Foundation’s reserves can cover annual granting activities at current levels for 5.3 years.

BC Cancer Foundation reports using external fundraisers as part of its fundraising efforts in its most recent F2019 T3010 filing. In F2019, it paid $1.0m to external fundraisers that raised $2.7m. With an external fundraising ratio of 37%, BC Cancer Foundation received 63 cents of every dollar donated to external fundraisers.

This report is an update that has been sent to BC Cancer Foundation for review. Comments and edits may be forthcoming.

Updated on June 22, 2020 by Katie Khodawandi.

Financial Review


Financial Ratios

Fiscal year ending March
202020192018
Administrative costs as % of revenues 7.4%8.2%8.8%
Fundraising costs as % of donations 23.5%22.6%22.7%
Total overhead spending 30.9%30.8%31.6%
Program cost coverage (%) 532.3%571.0%550.9%

Summary Financial Statements

All figures in $000s
202020192018
Donations 43,79743,48739,020
Government funding 10,00000
Special events 11,33212,66110,722
Investment income (5,453)5,5144,011
Other income 1,5151,487703
Total revenues 61,19163,14954,456
Grants 31,04528,53226,348
Administrative costs 4,9344,7304,446
Fundraising costs 12,94412,68811,310
Total spending 48,92345,95042,104
Cash flow from operations 12,26817,19912,352
Capital spending 0(375)(875)
Funding reserves 165,255162,920145,144

Note: To report on a cash basis, Ci adjusted grants for changes in accounts payable to BC Cancer, affecting total expenses by ($1.3m) in F2020, ($4.8m) in F2019, and $721k in F2018. Investment income includes unrealized losses, decreasing total revenue by $11.4m in F2020, $571k in F2019, and $778k in F2018. Ci removed amortization of $1k in F2019 and $3k in F2018 from administrative costs. F2019 T3010 CRA data was the most recent information available at the time this profile was updated.

Salary Information

Full-time staff: 67

Avg. Compensation: $109,199

Top 10 staff salary range:

$350k +
1
$300k - $350k
1
$250k - $300k
0
$200k - $250k
2
$160k - $200k
2
$120k - $160k
4
$80k - $120k
0
$40k - $80k
0
< $40k
0

Information from most recent CRA Charities Directorate filings for F2019

My anchor

Comments & Contact

Comments added by the Charity:

No comments have been added by charity

Charity Contact

Website: www.bccancerfoundation.com
This email address is being protected from spambots. You need JavaScript enabled to view it.

Print